进口或国产雷帕霉素支架治疗非左主干分叉病变对比分析

目的研究应用进口或国产雷帕霉素支架治疗非左主干分叉病变的临床疗效。方法入选接受冠状动脉（冠脉）双支架术治疗的冠脉非左主干真性分叉病变患者75例,随机选用进口或国产雷帕霉素药物洗脱支架治疗,完成6个月的临床随访,记录死亡、心绞痛、心功能不全、再发心梗、靶病变重建（TLR）或支架内血栓形成的发生率。结果 75例患者均完成了6个月的临床随访,死亡、再发心梗、再发胸痛、TLR、支架内血栓、心功能不全和MACE发生率在Firebird支架组分别为0%、0%、8.1%、0%、0%、2.7%、10.8%;在Cypher支架组分别为0%、0%、7.9%、0%、0%、2.6%、10.5%。两组间不良事件的差异无统计学意义（P〉0.05）。结论冠心病患者的真性分叉病变均成功置入国产雷帕霉素支架,与进口雷帕霉素支架相比,不良事件的差异无统计学意义。国产雷帕霉素支架在非左主干分叉病变治疗中是安全可靠的。

Treatment of Non-left Main Bifurcation Lesions Using the Rapamycin-Eluting Stent

Objective To investigate the effect of imported or domestic rapamycin-eluting stent in treatment of non-left main bifurcation lesions.Methods 75 cases with non-left main bifurcation lesions were randomized treated with imported or domestic rapamycin-eluting stent,and 6 months of follow-up.Results There were no difference in death,angina pectoris,myocardial infarction,TLR,stent thrombosis in two groups.Conclusion The treatment effect of domestic rapamycin-eluting stent on non-left main bifurcation lesions was safe and effective.